Press Releases for optr

Press Releases
Squawk Box Stocks Reports On: ReneSola Ltd. (NYSE: SOL), SemiLEDs Corporation (NASDAQ: LEDS), Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR), SIRIUS XM Radio Inc. (NASDAQ: SIRI)
Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer
Pre-Market Analysis on Life Technologies, Quest Diagnostics, Brookdale Senior Living, Antares Pharma, and Optimer Pharma
The Dow Jones Hits New Record. Merz Pharma Group Interested In Buying Obagi for About $383.5M
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Optimer Reports Fourth Quarter and Fiscal Year 2012 Financial Results
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Optimer Pharmaceuticals' Board of Directors Appoints Board Chairman, Dr. Henry McKinnell, Chief Executive Officer
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Optimer Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference
Our Pros Knew OCZ, VELT, CEDC and OPTR Would Be Top Gainers on Monday
Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
Optimer Pharmaceuticals and AstraZeneca Collaborate to Commercialize Fidaxomicin for Clostridium Difficile Infection in Latin America
Optimer Initiates Phase 3b Clinical Trial of DIFICID? for the Prevention of Clostridium difficile-Associated Diarrhea in Bone Marrow Transplant Patients
New Research to be Presented at IDWeek 2012
Optimer Pharmaceuticals to Sell Remaining Ownership in Optimer Biotechnology, Inc. for U.S. $60 Million
Optimer Introduces Strategic Initiative to Further Facilitate Patient Access to DIFICID?
Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
CMS Grants New Technology Add-on Payment to DIFICID? for Treatment of Clostridium difficile-associated Diarrhea
Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
Optimer Pharmaceuticals, Inc. [OPTR] to Ring The NASDAQ Stock Market Opening Bell
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
Media Advisory - Infectious Diseases Specialist to Discuss Advancement in the Treatment of Clostridium difficile Infections (CDI) in Canada
DIFICID(tm) (fidaxomicin), a first-in-class antibiotic, now approved in Canada to treat C. difficile, a serious and life-threatening infection
Optimer's DIFICID? (fidaxomicin) Tablets Approved by Health Canada for the Treatment of Clostridium Difficile Infection and now Available to Canadian Patients
Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
First sales of DIFICLIR(tm) by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
Optimer Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
Analysis of Data from Two Phase 3 Studies Shows DIFICID? Offered Faster Diarrheal Symptom Improvement than Oral Vancomycin in Patients with Cancer Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2012 Financial Results
Harwood Feffer LLP Announces Investigation of Optimer Pharmaceuticals, Inc.
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Optimer Pharmaceuticals, Inc.
Optimer Pharmaceuticals Announces Personnel Changes
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)
Optimer Pharmaceuticals, Inc. and Astellas Pharma Inc. Enter Collaboration to Commercialize Fidaxomicin for Clostridium difficile Infection in Japan
Optimer Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference
The Lancet Infectious Diseases Publishes Phase 3 Study Results Confirming Superior Rate of Sustained Clinical Response of DIFICID? (fidaxomicin) Tablets Compared to Oral Vancomycin in Adult Patients with Clostridium difficile Infection (CDI)
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
The European Commission Grants Marketing Authorization for DIFICLIR(tm) (fidaxomicin) Tablets for Treatment of Clostridium difficile Infections
Data Suggest Optimer's DIFICID? Provides Economic Value in the Treatment of Clostridium difficile-associated Diarrhea
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Optimer Pharmaceuticals to Present at Oppenheimer's 22nd Annual Healthcare Conference
Optimer Pharmaceuticals to Webcast Investor and Analyst Reception on December 5th
Optimer Files New Drug Submission for DIFICID(tm) in Canada, Creates Canadian Subsidiary to Lead Commercial Effort
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results
DIFICID(tm) Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
Optimer Pharmaceuticals' DIFICID Featured in Presentations at 49th Annual Meeting of IDSA
LifeSci Advisors Publishes DIFICID Survey Results
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
CHMP Recommends Astellas Pharma Europe Ltd.'s (APEL) DIFICLIR(tm) for Approval in the EU
Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID(tm)
Optimer to Provide DIFICID(tm) Launch Update at Morgan Stanley Global Healthcare Conference
Optimer Pharmaceuticals' DIFICID Featured in 11 Presentations at 51st ICAAC
Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID(tm) (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receiving Concomitant Antibiotics
Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
Optimer Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
FDA Approves Optimer's DIFICID(tm) (fidaxomicin) Tablets for the Treatment of Patients with Clostridium difficile-Associated Diarrhea (CDAD)
DIFICID(tm) Data Presented at American Geriatric Society Annual Meeting Demonstrates that Advancing Age is Associated with Progressive Deterioration of Treatment Outcomes in Patients with Clostridium difficile Infection
Data Presented at ECCMID Illustrate Risk Factors for Negative Outcomes in C. Difficile Patients
Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID(tm) Phase 3 Data
Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
Optimer Pharmaceuticals Expands Senior Management Team
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
Cubist Pharmaceuticals 1Q11 Total Net Revenues Up 13% to $162.5 Million; 1Q11 U.S. Net Revenues for CUBICIN Up 14% to $153.7 Million
Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID(tm) (Fidaxomicin) for Clostridium difficile Infection in the United States
Optimer Announces that the U.S. Food and Drug Administration's Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid(tm) for Treatment of Patients with Clostridium difficile infection (CDI)
Trading Halted Today in Optimer Pharmaceuticals Stock
Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
Optimer Pharmaceuticals Appoints Glenn Tillotson, Ph.D., to Senior Vice President of Medical Affairs and Announces Executive Promotions
Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
Optimer Pharmaceuticals to Present at February 2011 Investor Conferences
The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI)
Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
Optimer Pharmaceuticals Announces Key Additions to Management Team

Two Week FREE Trial

Company

Community

Analysis

Charts

Analyst

Ratios